Company Overview
Silence Therapeutics plc is a biotechnology firm focused on the discovery and development of novel molecules that utilize short interfering ribonucleic acid (siRNA) technology to inhibit the expression of specific target genes within the fields of hematology, cardiovascular, and rare diseases. The company operates within the Healthcare sector, specifically the Biotechnology industry, which characterizes an environment of high risk and high reward where innovation in molecular biology drives potential therapeutic breakthroughs. Currently, the organization employs 88 individuals and holds a market capitalization of $232.86M, generating total revenue of $559,000 over the trailing twelve months. These financial figures indicate that Silence Therapeutics functions as a small-cap entity with minimal revenue generation relative to its market valuation, reflecting the typical capital-intensive nature of early-stage biotechnology firms that prioritize research and development expenditures over immediate profitability. The discrepancy between its substantial market cap and negligible annual revenue suggests that the company's valuation is driven primarily by the perceived potential of its pipeline assets, such as Divesiran, rather than current operational cash flows.
Financial Health
Silence Therapeutics reported revenue of $559,000 for the trailing twelve months, with a net income of $-88,612,000 and EBITDA of $-81,735,000. The significant gap between the minimal revenue figure and the substantial net loss reveals a cost structure dominated by heavy research and development expenses, where operating costs vastly exceed the revenue generated from current product sales. The company recorded free cash flow of $-39,550,248, indicating a continuous burn rate that consumes liquid assets and necessitates ongoing capital raising to fund future clinical trials and development activities. Financial margins further illustrate this operational reality, with a gross margin of 61.5%, an operating margin of -37150.0%, and a profit margin of 0.0%. While the positive gross margin suggests efficient manufacturing costs relative to sales, the extreme negative operating margin highlights the immense overhead associated with clinical-stage biotechnology operations, and the zero profit margin confirms that the company has not yet achieved commercial profitability. Regarding solvency, the company holds $85.11M in cash against $160,000 in debt, supported by a debt-to-equity ratio of 0.26. This balance sheet structure indicates a highly conservative financial position with negligible leverage, as the company's cash reserves far exceed its outstanding liabilities. The current ratio stands at 8.72, which signifies robust short-term liquidity and a strong ability to cover current obligations with available current assets. Return metrics show a return on equity of -90.3% and a return on assets of -30.8%, revealing that management effectiveness is currently measured by the preservation of capital rather than the generation of returns, as negative returns are standard for pre-revenue biotechnology companies burning through funding to reach commercial milestones.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the absence of earnings, while the forward P/E is -6.85, a metric that implies the market is pricing in future earnings recovery but reflects current unprofitability in standard valuation terms. The price-to-book ratio is 3.74, indicating that the market values the company at a significant premium over its tangible book value, a common occurrence for firms with valuable intellectual property that is not fully captured on the balance sheet. Alternative valuation metrics provide further insight, with a price-to-sales ratio of 416.57 and an EV/EBITDA of -7.51, suggesting that investors are paying a high multiple for each dollar of revenue to secure access to the company's potential pipeline. The stock's trading range over the past year spans from a 52-week low of $1.97 to a 52-week high of $7.91, meaning the current price sits within this established volatility band. The beta value is 1.35, which indicates that the stock price exhibits higher volatility relative to the broader market, moving 35% more aggressively than the benchmark index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year stands at -99.9%, while earnings growth is N/A, reflecting the transition from a period of revenue generation to one where the company has likely ceased generating sales to focus entirely on development. The negative revenue growth rate indicates a contraction in current sales figures, which is typical for biotechnology companies that may be pausing commercial activities to prioritize clinical development phases. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically reinvested into the business, although in this specific case, the earnings are negative, meaning the company relies on external capital for reinvestment rather than internal cash flow. The overall growth and income profile is characterized by a lack of current commercial scale and income generation, with the company's value proposition resting entirely on the potential future success of its drug candidates rather than historical or current financial performance.